Amgen (AMGN)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-15
$375.65-1.53%
Close 2026-09-15 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-15
Research Workspace
Put AMGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near guidance mid-point: EPS guidance mid $16.44 vs target $16.36.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 15% growth a year, above the roughly 5% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAmgen's growth relies on sustaining revenue from its broad portfolio and innovation. Recent earnings showed a 10% revenue increase, with a strong beat in Q2. Amgen trades at 17× P/E, below the peer median of 22×, indicating the market prices in more growth than expected. The primary risk is a potential guidance cut, with an 11% miss probability for the next quarter. Peer multiples imply a price about 17% below where it trades. Our read is provisional.
Trailing returns as of 2026-09-15. AMGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 36 analysts currently covering AMGN (as of Sep 2026).
Based on 17 Wall Street analysts offering 12-month price targets for AMGN in the last 4 months.
Continue this research
Compare AMGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AMGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put AMGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance MariTide through Phase 3 clinical trials
Highlights progress on MariTide aligns with product advancement goals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $375.65
The last 12 months of price, then the range of analyst 12-month targets from today’s $375.65.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance MariTide through Phase 3 clinical trials
FDA approval supports advancement of MariTide in trials.
Advances: Advance MariTide through Phase 3 clinical trials
IMDELLTRA momentum supports advancement of MariTide.
Conference highlights growth strategies aligning with management's objectives.
Advances: Grow key product sales with volume growth despite pricing pressures
Imdelltra sales growth supports key product sales objective.
Threatens: Advance MariTide through Phase 3 clinical trials
Concerns about olpasiran could hinder product advancement.
Threatens: Advance Repatha cardiovascular outcomes studies
Rivals' failures could impact Repatha's market position.
Novartis trial failure raises concerns for Repatha's market position.
